Oral Biolife was founded in 2022 to offer PiezoGEL, a piezoelectric hydrogel to treat periodontal disease.
As CEO, Mr. Breitenbach will oversee operations and research and development as well as the launch of PiezoGEL, according to a June 5 news release.
Mr. Breitenbach has more than 25 years of experience serving in executive roles in the pharmaceutical, biopharmaceutical and biotech industries.
At the Becker's 5th Annual Future of Dentistry Roundtable, taking place September 14-15 in Chicago, dental leaders and executives will gain insights into emerging technologies, practice growth strategies and the evolving landscape of dental care delivery, with a focus on innovation, patient experience and operational excellence. Apply for complimentary registration now.
